Ross Dickins is an Associate Professor at the Australian Centre for Blood Diseases, Monash University. His laboratory uses genetic technologies and mouse models to investigate novel therapeutic strategies for acute leukaemia, and has also developed biologics that modulate T cell checkpoints in autoimmunity and cancer. In 2022 he co-founded Monash spinout company FLEX Immunotherapeutics.